+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists



The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists



Skin Therapy Letter 9(2): 1-5



Atopic dermatitis (AD) is a chronically relapsing eczematous disorder of the skin that occurs in persons of all ages but is more common in children. AD is associated with other atopic diseases such as allergic rhinoconjuntivitis or bronchial asthma. Nearly 80% of children with AD eventually develop allergic rhinitis or asthma. AD can be classified as mixed (cases associated with respiratory allergies) and pure . Pure AD has intrinsic and extrinsic variants. In the extrinsic type, interleukin-4 is secreted by T-cells isolated from spontaneous lesions and skin-derived T-lymphocytes express more IL-13. Due to the different immunopathogenesis, it has been suggested that antileukotriene agents may be more successful in the treatment of the extrinsic subgroup. Leukotrienes (LTs) are a class of potent biological inflammatory mediators derived from arachidonic acid through the 5-lipoxygenase pathway. There is evidence of enhanced LT production in the pathogenesis of AD. Evidence in the literature provides a pathophysiological rationale for the use of cysLT receptor blockers in the treatment of AD. However, the exact mechanism of action of leukotriene receptor antagonists in AD is not known. In small clinical and case studies, montelukast was found to be a safe and effective alternative or steroid-sparing therapy in the management of patients with atopic dermatitis.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050747539

Download citation: RISBibTeXText

PMID: 14749843


Related references

Leukotriene receptor antagonists--possible therapeutic option in the treatment of atopic dermatitis. Polski Merkuriusz Lekarski 14(79): 86-88, 2003

A role for leukotriene antagonists in atopic dermatitis?. American Journal of Clinical Dermatology 2(1): 1-6, 2001

Leukotriene receptor antagonists are ineffective for severe atopic dermatitis. Journal of the American Academy of Dermatology 50(3): 485-486, 2004

Leukotriene receptor antagonists--a novel therapeutic approach in atopic dermatitis?. Dermatology 203(4): 280-283, 2001

Leukotriene Receptor Antagonists – A Novel Therapeutic Approach in Atopic Dermatitis?. Dermatology 203(4): 280-283, 2001

Chemical mediators in atopic dermatitis: involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis. Journal of Allergy & Clinical Immunology 103(4): 663-670, 1999

Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. Journal of the American Academy of Dermatology 77(1): 177-180, 2017

Leukotriene receptor antagonism may not be effective in atopic dermatitis treatment after all. Journal of Clinical Pharmacy and Therapeutics 43(1): 159-162, 2017

A leukotriene antagonist (montelukast) in the treatment of atopic dermatitis in pediatric patients. Revista Alergia Mexico 50(5): 187-191, 2003

Targeted UVB-308 nm (NUVB) therapy with excimer laser in the treatment of atopic dermatitis and other inflammatory dermatoses. Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 60(11): 898-906, 2010

Itch characteristics in five dermatoses: non-atopic eczema, atopic dermatitis, urticaria, psoriasis and scabies. Acta Dermato-Venereologica 93(5): 573-574, 2014

Therapeutic Hotline: Cysteinyl leukotriene receptor antagonist montelukast in the treatment of atopic dermatitis. Dermatologic Therapy 23(1): 90-93, 2010

Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast. Acta Dermatovenerologica Alpina, Pannonica, et Adriatica 14(3): 115-119, 2005

Eosinophil-derived leukotriene C4 signals via type 2 cysteinyl leukotriene receptor to promote skin fibrosis in a mouse model of atopic dermatitis. Proceedings of the National Academy of Sciences of the United States of America 109(13): 4992-4997, 2012

CysLT1 antagonists in the treatment of atopic dermatitis and urticaria. Clinical & Experimental Allergy Reviews 1(3): 305-308, 2001